• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Robust Score Can ID Infection Risk in Newly Diagnosed Multiple Myeloma

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 19, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 19, 2023 -- A robust score can identify patients with newly diagnosed multiple myeloma (NDMM) at risk for severe infection/death, according to a study published online Dec. 7 in Leukemia.

Elias K. Mai, M.D., from the University Hospital Heidelberg in Germany, and colleagues examined 3,700 transplant-eligible NDMM patients treated in 2005 to 2020 with novel agent-based triplet/quadruplet induction therapy (IT). The patients were categorized into a training cohort (1,333 patients) and three validation cohorts (2,367 patients).

The researchers found that 11.8, 1.8, and 12.5 percent of patients in the training cohort experienced severe infections, death, or both, respectively, during IT. Low platelet count (<150 n/L), International Staging System III, higher World Health Organization performance status (>1), and age (older than 60 years) were identified as major baseline risk factors for severe infection/death. In the low- versus intermediate- versus high-risk groups, the risk for severe infection increased from 7.7 to 11.5 to 23.3 percent, respectively. In three trials incorporating quadruplet IT with an anti-CD38 antibody, the risk score was independently validated.

"Our study highlights the importance of early severe infections and death in the era of novel agent-based therapy in patients with NDMM," the authors write. "Based on our risk score, patients at high risk of early, severe infections and death can be easily identified upfront, when evaluated for the latest quadruplet induction therapies including an anti-CD38 monoclonal antibody."

Several authors disclosed ties to the biopharmaceutical industry, including several companies that funded the trials.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.